ClinicalTrials.Veeva

Menu
U

University of Louisville | James Graham Brown Cancer Center

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
Docetaxel
cisplatin
Oxaliplatin
Ipilimumab
paclitaxel
Cisplatin
Brivanib
SU5416
Irinotecan

Parent organization

This site is a part of University of Louisville

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 127 total trials

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse....

Active, not recruiting
Cytochrome P-450
Antineoplastic Agents, Hormonal
Drug: Placebo for Abemaciclib
Drug: Abemaciclib

Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor...

Active, not recruiting
Endometrial Cancer
Non-small Cell Carcinoma
Drug: Pembrolizumab
Drug: RGX-104

The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared...

Active, not recruiting
Advanced/Metastatic Gastroesophageal Adenocarcinoma
Drug: 5-FU
Biological: Lenvatinib
Locations recently updated

The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus ch...

Enrolling
Metastatic Esophageal Squamous Cell Carcinoma
Drug: Oxaliplatin
Drug: Levoleucovorin

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizum...

Enrolling
Solid Tumors
Hematologic Malignancies
Drug: Pembrolizumab
Drug: Lenvatinib

This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.

Enrolling
Melanoma
Lung Cancer
Biological: OBX-115

This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular ca...

Active, not recruiting
Hepatocellular Carcinoma
Biological: Pembrolizumab
Drug: Placebo

This Phase III clinical study will assess the impact of BMN 270 (compared to FVIII prophylaxis) on the number of bleeding episodes irrespective of ex...

Active, not recruiting
Hemophilia A
Biological: valoctocogene roxaparvovec

Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymp...

Active, not recruiting
Cervical Carcinoma
Biological: LN-145 + pembrolizumab
Biological: LN-145

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery...

Active, not recruiting
Breast Cancer
Biological: Pembrolizumab (K)
Radiation: Radiation therapy

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early...

Enrolling
Locally Advanced or Metastatic Non-small Cell Lung Cancer
Locally Advanced or Metastatic Castration-resistant Prostate Cancer
Drug: PF-07220060
Drug: Fulvestrant

Trial sponsors

R
University of Louisville (UOFL) logo
Merck Sharp & Dohme (MSD) logo
Bristol-Myers Squibb (BMS) logo
A
Lilly logo
Novartis logo
Pfizer logo
Alliance for Clinical Trials in Oncology logo
B

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems